Dan Wildman

Dan Wildman currently serves as an Independent Director and Strategic Advisor at PanTher Therapeutics, and as an Independent Director at Nyxoah, where involvement includes Audit and Remuneration Committees. Additionally, Wildman holds the position of Director at UroGen Pharma, chairing the Compliance Committee, and is Chairman of the Board at Progenerative Medical, Inc. Previous experience includes an Independent Director role at Precision Healing before its acquisition by Sanara MedTech, along with extensive leadership positions at Johnson & Johnson from 2000 to 2018, where responsibilities spanned global management and strategic growth across multiple divisions. Wildman began their career in strategic marketing at Boston Scientific before receiving a BS in Economics from St. Lawrence University.